Corporate Profile
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpio’s lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications.
Stock Information ARPO (Common Stock) $1.22 - 3.03 (71.29%)
ExchangeNASDAQ CM
Volume6,744,623
Today's Open$1.40
Previous Close$4.25
Data as of 03/18/19 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

 
Stock chart for: ARPO.O.  Currently trading at $1.22 with a 52 week high of $5.20 and a 52 week low of $1.56.
Upcoming Events
Monday, March 18, 2019
Aerpio Pharmaceuticals Conference Call